Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEVANT
2023-507879-21-00Phase 2Authorised
- Sponsor
- Technische Universität Dresden
- Start
- Mar 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Treosulfan + fludarabine conditioning with PTCy with Melphalan + fludarabine conditioning with PTCy (2 arms). Primary endpoint: Overall survival. Planned start Mar 2025; status: authorised.
02
Drugs
treosulfanmelphalanfludarabinecyclophosphamide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2023-507879-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507879-21-00.